Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
1.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

161
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
161
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

404
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
404

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Treatment of Vascular Anomalies With Sirolimus: Characterizing Practice Patterns of US Specialist Clinicians.

Pediatric blood & cancer·2026
Same author

An MIEN1-based hexamer peptide (LA3IK) inhibits EGF-driven oncogenic signaling in prostate cancer by disrupting EGFR-ERBB2 heterodimerization.

Scientific reports·2026
Same author

Cytokine MicroRNA regulatory networks in colorectal cancer: Contemporary research insights and mechanistic analysis.

Cytokine & growth factor reviews·2026
Same author

Incidence and outcomes of treatment-associated hepatotoxicity during pediatric acute lymphoblastic leukemia induction therapy: a Reducing Ethnic Disparities in Acute Leukemia (REDIAL) Consortium report.

Haematologica·2026
Same author

Preface.

Critical reviews in oncogenesis·2025
Same author

Evaluation of Mithramycin in Combination with Chemotherapeutic Agents Against Ewing Sarcoma Cell Lines.

Cancers·2025

Related Experiment Video

Updated: Apr 29, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K

Targeted nanoparticles for pediatric leukemia therapy.

Riyaz Basha1, Nirupama Sabnis2, Kenneth Heym3

  • 1Department of Pediatrics, University of North Texas Health Science Center , Fort Worth, TX , USA ; Institute for Cancer Research, University of North Texas Health Science Center , Fort Worth, TX , USA.

Frontiers in Oncology
|May 27, 2014
PubMed
Summary

New nanotechnology approaches, specifically high-density lipoprotein-based drug delivery systems, show promise for treating childhood leukemia. These methods aim to improve drug efficacy and reduce toxic side effects in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) treatment.

Keywords:
drug delivery systemshigh density lipoproteinleukemiananoparticlestargeting

More Related Videos

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

10.0K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

8.1K

Related Experiment Videos

Last Updated: Apr 29, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

17.5K
Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors
11:52

Analysis of Targeted Viral Protein Nanoparticles Delivered to HER2+ Tumors

Published on: June 18, 2013

10.0K
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
08:03

Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles

Published on: December 1, 2016

8.1K

Area of Science:

  • Oncology
  • Nanotechnology
  • Pediatric Medicine

Background:

  • Acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) constitute a significant portion of childhood cancers.
  • Current treatments for childhood leukemia have limitations, including drug resistance and long-term toxicities.
  • There is a critical need for innovative therapeutic strategies to improve treatment outcomes and minimize side effects.

Purpose of the Study:

  • To review and evaluate lipoprotein-based nanoparticles, particularly high-density lipoprotein (HDL) systems, as drug delivery vehicles for childhood leukemia.
  • To highlight the potential of nanotechnology in enhancing the efficacy of anti-cancer agents for pediatric leukemia.
  • To address the gap in existing literature concerning lipoprotein-based nanocarriers in leukemia therapy.

Main Methods:

  • Literature review focusing on nanotechnology applications in cancer therapy.
  • Specific emphasis on high-density lipoprotein (HDL)-based drug delivery systems.
  • Analysis of nanoparticle characteristics, including size, composition, assembly, and performance evaluation.

Main Results:

  • Nanotechnology offers a promising avenue for improving drug bioavailability and therapeutic efficacy in cancer treatment.
  • Lipoprotein-based nanoparticles, especially HDL carriers, have been underrepresented in current reviews of nanomedicine for cancer.
  • HDL-based systems present a potential platform for targeted drug delivery in pediatric leukemia, warranting further investigation.

Conclusions:

  • High-density lipoprotein-based nanoparticles represent a novel and promising approach for the enhanced treatment of childhood leukemia.
  • Further research into HDL drug delivery systems could lead to reduced chemotherapy-related toxicities and improved long-term outcomes for pediatric cancer patients.
  • This review underscores the need for focused research on lipoprotein-based nanocarriers in the context of pediatric oncology.